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Abstract
Background: Hepatic impairment, portal hypertension, and multi-systemic damage could occur during liver cirrhosis’s late
stage. Bleeding is a complication of hepatic cirrhosis along with several changes including blood platelet count (BPC), mean
platelet volume (MPV), platelet crit (PCT) and expression of  platelet CD62P. Blood platelet count (BPC), mean platelet
volume (MPV), platelet distribution width, and other indices are indirect reflections of CD62P parameters.
Objective: To investigate the changes in platelet functional parameters and CD62 P expression in liver cirrhosis as a possible
guide in clinical treatments and prognoses of liver cirrhosis.
Methods: CD62P was tested by flow cytometry in liver cirrhosis. BPC, MPV, and PCT in peripheral blood were tested using
an auto blood cell analyzer. Data were analyzed using SPSS11.0.
Results: The values of CD62P and MPV in patients was significantly higher than those of healthy donors (P<0.01), while
the values of BPC and PCT were significantly lower than those of the control group (P<0.01)
Conclusions: CD62P, BPC, MPV, and platelet crit (PCT) show several changes in liver cirrhosis. It is useful to understand
the relationship between hepatic cirrhosis severity and CD62P, BPC, MPV, PCT, timely monitoring of  CD62P for treatment
of hepatic cirrhosis in clinical treatment and prognosis.
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Introduction
Cirrhosis is the final stage attained by various chronic
hepatic diseases after years or decades of slow
progression. It can thus be prevented by appropriate
screening for chronic liver diseases so that they can
be treated in time. Chronic liver diseases do not
usually cause any symptoms. However, hepatic
impairment, portal hypertension, and multi-systemic
damage could occur during the late stage of liver
cirrhosis. Moreover, hypersplenism1,2,
thrombocytopenia3-6, and consumption of blood
coagulation factors and antibodies directed against
platelets7-9 could lead to bleeding  tendency. Granula
protein on the platelet surface (CD62P) has very high
sensitivity and specificity to platelet activation; thus,
it is regarded as a special index of platelet activation10-
12. Platelets are formed by fragments of  macrophage
kytoplasm, and interact with mono-macrophages in
the spleen. The mean platelet volume (MPV) reflects
the active compounds and granula in the platelet.
The larger the size of the platelet, the more glycogen,
adenine, nucleotide, and normal phosphates it
contains and the higher its active functions become.
Smaller-sized platelets have lower functions. Blood
platelet count (BPC), MPV, and other indices are
indirect reflections of its parameters13. Reports show
that BPC, MPV, and platelet crit (PCT) exhibit some
changes in liver cirrhosis. Decreased MPV may be
related to the presence of endotoxins, as well as to
increased immunoglobulin, both having the ability
to induce sustained platelet activation, thereby leading
to the release of active compounds that cause granula
exhaustion, platelet shrinkage, and decreased
reservation14.
In this study, CD62P was tested by flow
cytometry in liver  cirrhosis. BPC, MPV, and PCT in
peripheral blood were tested using an auto blood
cell analyzer. Understanding the relationship between
hepatic cirrhosis severity and CD62P, BPC, MPV,
PCT, timely monitoring of  CD62P, and other
platelet parameters is highly essential in preventing
hemorrhage and coagulation disorders during the
early stage of  hepatic cirrhosis and may serve as a
guide in clinical treatments and prognoses.
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Methods
Patients
Up to 32 cases of hepatic cirrhosis were studied,
among whom  were 25 male and 7  female. Their age
range was 35-68 years, and the average age was 51±15.
The diagnostic criteria were in accordance with the
5th National Infectious Diseases and Parasite
Conference, and created from combined clinical
manifestations, liver  function, ultrasound, and CT scan
findings. The patients were classified according to by
Child–Pugh (REF) as follows: Grade A, 12 cases;
Grade B, 10 cases; and Grade C, 10 cases, which was
used for assessing the prognosis of  cirrhosis. The higher
score, the worse of  liver reserve function (Grade A,
5-6, the risk of  operation is low; Grade B, 7-9, the
risk of operation is higher than Grade A; Grade C,
e”10, the risk of operation is the highest and the
prognosis is the worst). All the patients had no heart,
brain, kidney, or diabetic problems; they were also not
suffering from acute infections. Six cases were
confirmed to have upper gastrointestinal tract bleeding
through gastroscope examination and a positive occult
blood (OB) test.
The control group comprising 20 cases of  normal
patients underwent a health checkup. Among the 20
cases, 10 were male and 10 were female, aged 21 to
50 years, with an average age of 38±12. All cases in
the patient group and in the control group did not
take any anticoagulant one week before the test. This
study was conducted in accordance with the declaration
of Helsinki. This study was conducted with approval
from the Ethics Committee of  Linyi People’s Hospital.
Written informed consent was obtained from all
participants.
Detection of CD62P
Approximately 2 ml of fasting blood samples from
both patient and control groups were collected with
3.84% citric acid sodium. Then the samples were
placed in 1% paraformaldehyde at 4 °C for 15 min.
The samples underwent centrifugation at 800r/min
for 5 min. The platelet-rich supernatant was then
separated. Up to 50 µl supernatant was mixed with
CD62P monoclonal antibody (Becton-Dickinson)
labeled with phycoerythrin, 20 ul aliquot was mixed
and used for testing, and another 50 µl platelet-rich
plasma was placed in a tube and mixed with phosphate
buffer solution (PBS) for use as control. Both tubes
were reacted for 20 min away from light, and then
mixed with 1 ml of  1% paraformaldehyde at 4 °C.
The tubes were poached with PBS and underwent
centrifugation at 2000 r/min for 5 min. The
supernatant was withdrawn and the procedure was
repeated twice, adjusting the platelet concentration to
10×109/L, preserving at 4°C, and testing with flow
cytometry assay (Becton-Dickinson) within 24 hours.
All data were analyzed using Cell Quest Plot software.
Platelet CD62P positive rate was obtained as a result.
Detection of  BPC, MPV, and PCT
Up to 2 ml samples with ethylenediaminetetraacetic
acid (EDTA) anticoagulant and special anticoagulant
(1.5 mg/ml to 2.2 mg/ml EDTA-K
2
) were taken from
both patient and control groups. Subsequently, they
were tested using an M-533 auto blood cell analyzer.
The process lasted for approximately 2 hours. Three
kinds of whole blood were used as control. When all
the results were within the normal range, samples were
taken.
Statistical analysis
Data were expressed using mean ± standard deviation
( x ±s). T-test was applied to obtain the mean of
subgroup comparison in both groups. The data in the
other group were tested with ANOVA. All data gathered
were analyzed with SPSS11.0. P < 0.05 was considered
statistically significant.
Results
Comparison of  plasma CD62P, BPC, MPV, and
PCT
The testing results of  CD62P, BPC, MPV, and PCT
in the 32 cases of hepatic cirrhosis and in the 20 cases
from the control group are shown in Table 1. CD62P
and MPV in the cirrhosis group were higher than those
in the control group (P < 0.05), whereas BPC and
PCT were lower in the control group (P < 0.05). The
differences are presented in table 1.
Table 1: Result of  CD62P, BPC, MPV, and PCT in cirrhosis group and control group (X±s)
Groups Case CD62P (%) BPC (109/L) MPV (fl) PCT (%)
Cirrhosis 32 11.84±7.82* 43.96±21.69* 13.26±0.41* 1.06±0.72*
Control 20 2.74±1.05 95.14±21.75 9.73±0.80 1.98±0.35
Data were expressed using average ± standard deviation (
x
±s). T-test was applied to obtain the average of
subgroup comparison in both groups. P < 0.05 was considered statistically significant.
*Compared with control group, P < 0.05.
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Analysis of  CD62P, BPC, MPV, and PCT in liver
cirrhosis
The testing value of platelet surface CD62P in Grade
A cirrhosis patients was lower than that in Grade B
(P < 0.05). BPC, MPV, and PCT showed no
difference in both grades. The testing value of  platelet
surface CD62P in Grade C liver cirrhosis patients
was higher than that in Grades A and B (P < 0.05).
No marked difference was observed in various
grades (P > 0.05). The results of  CD62P, BPC, MPV,
and PCT in different grades are shown in table 2.
Analysis of  CD62P, BPC, MPV, and PCT in
bleeding or non-bleeding group
The testing value of platelet surface CD62P
(24.79±6.55) was markedly higher than that in the
no-bleeding group (8.85±4.21) (P < 0.01), whereas
BPC, MPV, and PCT exhibited no significant
difference. The testing values of  CD62P, BPC, MPV,
and PCT in the upper digestive bleeding with hepatic
cirrhosis group and in the non-bleeding group are
shown in table 3.
Table 2: Testing result CD62P, BPC, MPV, PCT of  platelet surface (X±s)
Group Case CD62P (%) BPC (109/L) MPV (f l) PCT (%)
Grade A 12 6.68±2.31 52.00±21.67 10.51±0.39 1.32±0.51
Grade B 10 9.20±4.06* 40.50±22.14 11.76±0.52 1.24±0.76
Grade C 10 20.67±7.61** 37.50±17.54 13.26±0.41 1.06 ±0.72
Data were expressed using average ± standard deviation (X±s). T-test was applied to obtain the average
of  subgroup comparison in both groups. P < 0.05 was considered statistically significant.
Grade B compared with Grade A, P < 0.05; Grade C compared with Grade A and B, P < 0.05
Table 3: Result of  CD62P, BPC, MPV, and PCT on surface of  platelet in upper digestive
bleeding and non-bleeding group with hepatic cirrhosis (±s)
Group case CD62P (%) BPC (109/L) MPV(fl) PCT (%)
Bleeding 6 24.79±6.55* 35.67±27.80 11.20±1.20 1.05±0.71
Non-bleeding 26 8.85±4.21 46.58±21.90 10.60±0.80 1.31±0.50
Data were expressed using average ± standard deviation (
x
±s). T-test was applied to obtain the average of
subgroup comparison in both groups. P < 0.05 was considered statistically significant.
*Comparison between bleeding group and non-bleeding group, P < 0.05.
Discussion
CD62P is a surface maker for platelet activation,
which is present in the granules of  platelets. CD62P
is a member of  selectin family. It is expressed by
activated platelets, megakaryocytes, and vascular
endothelial cells. It is one of  the important membrane
proteins, which serve  for coagulation15. CD62P
mediates the interaction between platelets and other
cells, platelets aggregation and adherence by
improving the interaction of  cells. Platelets originate
from bone marrow megakaryocytes and the number
of megakaryocytes indicates the function of
hematogenesis in the bone marrow. The testing value
of  BPC reflects the generation and decay of  platelets.
MPV reflects the metabolization of bone marrow
megakaryocytes. PCT is a parameter reflecting the
condition of granula and active substances in
platelets. Thus the detection of  BPC, MPV and PCT
in peripheral blood is used for treatment of liver
cirrhosis clinically16-17 since bleeding is a complication
of  liver  cirrhosis.
This study showed that CD62P in liver cirrhosis
patients was higher than that in the control group,
whereas the number of platelets were lower  in the
control group. This finding indicates that the increase
in CD62P was related to the overdestruction and
activation of  platelets in vivo. Therefore, CD62P in
hepatic cirrhosis patients was higher than that in the
control group. CD62P was also related to the Child-
Pugh classification, indicating that the platelets were
highly activated. To some extent, the destruction of
platelets along with the severity of liver cirrhosis
increased the value of CD62P and destroyed more
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platelets. Meanwhile, CD62P was higher in the group
with liver   cirrhosis combined with upper GI
bleeding than in the non-bleeding group, indicating
the relation of platelet activation and liver cirrhosis
severity. Therefore, testing the value of  CD62P
revealed the severity of  cirrhosis. The number of
platelets in various groups did not exhibit marked
difference, indicating that this factor was not related
to upper digestive bleeding. However, the number
of platelets was related to platelet function. Thus,
CD62P is a good index that can be used to determine
the activation and function of  platelets.
This study found that the number of platelets
and PCT was lower in liver cirrhosis patients, but
their MPV was increased. Thompson et al.18
postulated  that large-volume platelets contain more
body density, higher activity, more rapid metabolism,
more powerful adhesive capacity, and more bleeding.
They found that MPV and CD62P were higher in
liver cirrhosis patients than in the control group,
whereas BPC and PCT were lower in hepatic
cirrhosis patients than in the control group, indicating
the decrease in the number of platelets and the change
in quantity. The increase in CD62P and MPV could
cause hypersplenism and destroy platelets19, 20. The
mononuclear macrophage system compensated for
the excretion of large-volume platelets, whereas the
platelets themselves exhibited morphology changes,
such as giant cells and abnormities, possibly meeting
the body’s coagulate function requirement.
Conclusion
Dynamic monitoring of the expression of CD62P
and the parameters of platelets is helpful in
ascertaining the activities and function status of
platelets. It is also useful in discovering early bleeding
and coagulation disorders caused by hepatic cirrhosis,
thus leading to early and accurate treatment and
prognosis. Furthermore, results obtained from the
dynamic monitoring of the expression of CD62P
and the parameters of  platelets can serve as guidelines
for clinical treatments and prognosis. .
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